Date post: | 29-Feb-2016 |
Category: |
Documents |
Upload: | ovyanda-eka-mitra |
View: | 214 times |
Download: | 0 times |
of 108
Dwi Lestari PartiningrumNephrology and Hypertension Division,
Internal Medicine DepartmentMedical Faculty Diponegoro University/ Kariadi HospitalMedical Faculty Diponegoro University/ Kariadi Hospital
IntroductionIntroduction Glomerulonephritis (GN)o Initially coined by Klebs.oA group of diseases occuring either as primaryoA group of diseases occuring either as primary
renal disorders or a secondary manifestation of a sistemic disease statesistemic disease state.
o Inflammation within the glomerulus.oRenal manifestation of hematuria, proteinuria
and impaired glomerular filtrationp goUnpredicteble disease course make clinical
management problematicmanagement problematic
Dwi-Lestari
DEFINITION
Glomerulonephritis: (GN) injury withGlomerulonephritis: (GN) injury with evidence of inflammation such as l k t i filt ti tib d d itileukocyte infiltration, antibody deposition, and complement activation.
GN primary: pathology is confined to the kidney.p y p gy y GN secondary: when part of a multisystem disorder.
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
EM : Normal glomerular capilaryEM:Normalglomerularcapilary
Dwi-Lestari
NOMENCLATURE
Acute: glomerular injury occurring over days orAcute: glomerular injury occurring over days or weeks.
Sub acute or rapidly progressive (RPGN): over eeks or a fe monthsweeks or a few months.
Chronic: over many months or years.
Dwi-Lestari
I j L li tiInjuryLocalization
1. Overview of slides : assesses injury and localizes to the specific anatomic compartmentlocalizes to the specific anatomic compartment(glomerular/ vascular/ tubulointerstitial).
2. Assessment of type of injury, extent of injury in h l leach glomerulus.
Terminology : diffuse, focal, global and segmental.
Dwi-Lestari
Diffuse : at least 60% glomeruli involved.
Focal : some glomeruli < 60%.
Global : involved 1 glomerulus as a whole.
Segmental : part of 1 glomerulusSegmental : part of 1 glomerulus.
Dwi-Lestari
P lif ti l l ll b Proliferative : glomerular cell number (intracapillary and extracapillary)
A crescent: is a half-moon shaped. Cells in Bowman`s space.
Membranous : expansion of the GBM by immune deposits.p
Sclerosis : non-fibrilar extracellular material Fibrosis : Collagens type I and III Fibrosis : Collagens type I and III
Dwi-Lestari
Mechanism of Injury in Glomerulonephritis
Immuno pathogenesis
j y p
Immuno pathogenesis
G ti InflammationGeneticInfluence Genetic
Influence
Resolution ScarringResolution Scarring
Variable rateVariable rateof progression
Renal FailureDwi-Lestari
Immunologic Mechanism of Glomerular Injury
In situ antigen-antibody interaction (1) Exogenous planted antigens (1)
Circulating immune complexes (2)Circulating immune complexes (2) Intrinsic glomerular antigen (3)Cell mediated mechanism (?) Cell-mediated mechanism (?)
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
Activation of mediators of
l lglomerular injury
Activation of di t fmediators of
glomerular injury Dwi-Lestari
Mechanism of Immune Renal InjuryEtiologic Agent Infections
Loss of tolerance
Immune Response
IR Genes
Deposit Formation
AntibodyIgG, IgA T Cells
Deposit Formation
Mediation
In situ, complex trapping
Mediation
Eff t C ll
Complement, Chemokines Cytokines, Vasoactive
Effector CellsPMNs, macrophages Glomerular cells (mesangial prolif)
ResponseProliferation, PDGF Sclerosis, TGF - Dwi-Lestari
Complement activation
Dwi-Lestari
Dwi-Lestari
Glomerulonephritis Classification
Clinical Presentation (5 Clinical manifestation). Histopathological Classification: (percutaneus Histopathological Classification: (percutaneus
biopsy and open biopsy).Eti l d P th i Cl ifi ti Etiology and Pathogenesis Classification.
Immunological Classification.
Dwi-Lestari
Clinical Presentations of glomerular diseaseAsymptomatic
Proteinuria 150mgto3g/dayHematuria > 2 red blood cellsHematuria >2redbloodcells
Perhighpowerfield(>10x106 cells/LInspunurine(redbloodcells
Usuallydysmorphic
NephriticsyndromeOliguriai d ll
Nephrotic syndromeProteinuria;adult>3,5g/day
Hematuria :redcellscastsProteinuria;usually40mg/hperm2
EdemaHypercholesterolemia
Lipidemia
Chronic glomerulonephritis
OedemaAbruptonset
Lipidemia
RapidlyprogressiveglomerulonephritisRenal failure over days/weeksChronic glomerulonephritis
HypertensionRenalinsufficiensy
Proteinuria >3g/day
Renalfailureoverdays/weeksProteinuria usually
Definition of Clinical Syndrome
AcuteNephritic Nephrotic RPGNSyndrome Syndrome
Acute onset of : Insidious onset of : RPGN Hematuria Hypertension Oliguria
Proteinuria (severe) Edema (severe/ anasarca)
Hematuria w/ RBC cast Oliguria (variable) Oliguria
Edema (moderate) Proteinuria (mild-
) Hypoalbuminemia Hypercholesterolemia
Lipid ia
g ( ) Proteinuria (variable) Hypertension (unusual)moderate)
Azotemia
Lipiduria Hypercoagulability
(unusual)
Dwi-Lestari
Moderatehypertension
Mildhypertension
BPnormalBPnormalBloodpressure
HAEMATURIAmild
PROTEINURIAmild
PROTEINURIA3 5g +
PROTEINURIA3 5g +
Urinedipstick mildmild
Moderaterenal
Mildrenal
3.5g+3.5g+
GFR normalGFR normal
dipstick
GFR renalimpairment
impairmentGFRnormalGFRnormalGFR
Nephrotic syndrome Nephritic syndrome
Dwi-Lestari
Nephrotic and Nephritic PresentationNephroticandNephriticPresentation
Nephrotic Nephritic
Minimal change ++++Minimal changeMembranous nephropathy
++++++++
-+
Diabetic glomerulosclerosisAmyloidosis
++++++++
++y
FSGSMPGN
+++++
+++++MPGN
Acute post streptococcal GN+++
+++++++
Cresentic glomerulonephritis + ++++Dwi-Lestari
Gl l DiGlomerular Diseases
Nephritic Nephrotic Syndrome
Primary renal Post Infectious Minimal changeIg A nephropathy Focal SclerosisRPGN Membranous
nephropathyMembrano proliferative
Systemic Disease Vasculitis Diabetes MellitusWegeners Amyloid
Dwi-Lestari
Dwi-Lestari
Nephrotic Syndrome
Clinical features of nephrotic syndromeProteinuria (>3.5g/24h)
HypoalbuminaemiaOedema
+/- Hypercholesterolaemia
Dwi-Lestari
Nephrotic Syndrome PathophysiologyDiagnostic triadDiagnostic triadProteinuria > 3.5g/dLSerum Albumin < 30g/LOedema
Disease of glomerular capillary wallUrinary protein lossLow plasma oncotic pressureOedema Low plasma oncotic pressureSalt and water retention by kidneys
ComplicationsH h l t l i I d h ti th i d d dHypercholesterolemia Increased hepatic synthesis and reduced
metabolism of lipoproteinsThrombosis Venous obstruction caused by oedema
Increased hepatic synthesis of clotting factorsurinary loss of anti thrombotic protein (prot C,prot S, ATIII)
Infections Urinary loss of immunoglobulins and other defence protein
Renal Failure Intravascular volume depletion (acute)Renal Failure Intravascular volume depletion (acute)Intrarenal oedema (acute)Primary renal disease causing glomerular damageProteinuria causing interstitial inflamationProteinuria causing interstitial inflamation
Malnutrition Severe protein loss
Underfill OverfillFormation of nephrotic edema
Underfill
Proteinuria
Overfill
TubularDefect causing
Sodium retentionHypoalbuminemia
Sodium retention
Plasma colloidOncotic pressure Normal/raised
Plasma volume
Reducedplasma volume
Vasopresin Atrial natriureticPeptide (ANP)Normal/low
Renin angiotensinSystem activated
Aldosteron Vasopressin
normalANP Aldosteron
Waterretention
Sodiumretentionretention
Edema
retention
Dwi-Lestari
Lipid abnormalities VLDL deposition inVLDL deposition inin nephrotic syndrome
VLDLVLDL
Catabolism
VLDL deposition in vascular tissues VLDL deposition in vascular tissues
IDLIDLHepatic synthesis
Catabolism Endhotelial
lipoprotein lipase
O idi dLDLLDL
OxidizedLDL
Ath i itAth i itHepatic
secretionHDLHDL AtherogenicityAtherogenicity
Urine clearance
secretion HDL
HDL3HDL3Urine clearance of smaller HDL3
Cholesterol removal from tissue to liver
Lecithin cholesterol
acyltransferase
Lipoprotein( )
Lipoprotein( )
HDL2HDL2from tissue to liver
impaired
AtherogenicityAtherogenicity
y(LCAT) activity
(a)(a) AtherogenicityAtherogenicity
Dwi-Lestari
Coagulation abnormalities in Nephrotic Syndrome
Coagulation proteins
Raised: fibrinogen, Hepatic
synthesis
g ,factors V, VII, von Willebrand factor, protein C 1 -
l b liUrine
Unchanged/reduced:Prothrombin factors
IX X XI XII
macroglobulin clearance Hyperlipidemia
Accelerated IX, X, XI, XII, antithrombin III
Platelets aggregability
Accelerated atherogenesis
Platelets aggregability
Volume concentrationHemoconcentration
Immobility
A t i l th b i VenousArterial thrombosis Venous thromboembolism
Dwi-Lestari
asymptomatic proteinuriaasymptomatic proteinuriay p py p p
Quantitate protein excretionQuantitate protein excretionMeasure glomerular filtration
rate (GFR)Measure glomerular filtration
rate (GFR)Normal GFR
Non-nephrotic proteinuria
Normal GFRNon-nephrotic
proteinuria
Reduced GFR
Reduced GFR
Dipstick negative
Orthostatic proteinuria
Dipstick negative
Orthostatic proteinuria
Recumbentovernight
SerologictestsUltrasoundIfGFRorbloodproteinuria
No further action
proteinuriaNo further
actionPersistent
fixed proteinuria
Persistent fixed
proteinuriaConsider
renal biopsyConsider
renal biopsy
pressure(BP)abnormal,ifproteinuriaincreasesproteinuriaproteinuria
Reassess at 6-12 th
Reassess at 6-12 th
renal biopsyrenal biopsyincreases
Evaluation of isolated
12 monthsUrine protein
GFRBlood pressure
12 monthsUrine protein
GFRBlood pressure
If normal GFR and BP persist:
reassess
If normal GFR and BP persist:
reassess Evaluation of isolated asymptomatic proteinuria
pp reassess annuallyreassess annually
Dwi-Lestari
Glomerular Disease that causedGlomerular Disease that caused Nephrotic Syndrome
Mi i l h h ti d (MCNS) Minimal change nephrotic syndrome (MCNS) Focal segmental glomerulosclerosis (FSGS) Membranous nephropathy (MN) Membrano proliferative glomerulonephritis Membrano proliferative glomerulonephritis
(MPGN) Dense deposit disease Dense deposit disease Immunotactoid glomerulopathies (Amyloidosis)
Dwi-Lestari
LM EM IF
Histopathological Manifestation
LM EM IF
MCNS ( ) Foot proceses fusion ( )MCNSMN
Focal Sclerosing
(-)Thick GCW without glmhypercellularity
Foot proceses fusion
Subepithelial EDD (lumps)
(-)
Finely granular,CWg
GNMPGN
P t t GN
FSGSThick GCW with glmhipercelullarityHypercellular glms
Foot proceses fusionSubendothelial EDD, mesangial interposition.S b ith li l EDD (h )
IgM (segmental)CW Ig and C
Poststrep GNIgAN
DM
Hypercellular glmsMesangial proliferation
Glomerulo Sclerosis
Subepithelial EDD (humps)Mesangial EDD
Thick GBM mesangial
CW Ig and C3Mesangial IgA
CW pseudolinearDM
Amyloidosis VariableCongo red stain (+)
Thick GBM, mesangial expansion.Amyliod fibrils
CW pseudolinear
(-)
SLE
RPGN
Various patterns
crescents
EDD- multiple sites
variable
CW and mesangial Ig, C3, C1qCW (-) or granular or linearlinear
Dwi-Lestari
MINIMALCHANGENEPHROTICSYNDROME(MCNS)
Histopathology
LM : glomerular structure mainly normal IM IM : -EM : diffuse effacement of foot processes (podocytes).
Dwi-Lestari
EM : Fusion foot processes
Dwi-Lestari
FocalandSegmentalGlomerulosclerosis
LM : glomeruli may appear normal in early disease, later lesion show segmental areas of sclerosis and hyalinosislesion show segmental areas of sclerosis and hyalinosis of the glomerular tuft, expansion of mesangial matrix and interstitial fibrosis with tubular atrophy.interstitial fibrosis with tubular atrophy.
IF : negative, except for IgM and C3 in sclerotic lesion.EM :EM :
Idiopathic FSGS : diffuse effacement of foot processes and degeneration of podocytesand degeneration of podocytes
Secondary FSGS : patchy effacement of podocyte foot processesprocesses.
Dwi-Lestari
Perihilar segmentalPerihilar segmental sclerosis
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
Membranous Nephropathy (MN)
LM : GBM is thickened and the capillary wall more rigid th l i d d th ill ll i iththan normal; in advanced cases, the capillary wall is with spikes of GBM extending between and around subepithelial deposits. Advanced glomerular lesions are
i t d ith t b l t h d i t titi l fib iassociated with tubular atrophy and interstitial fibrosisIF : Granular glomerular capillary wall deposits of IgG
C3 are characteristics even if light microscopy is normalC3 are characteristics even if light microscopy is normalEM : Subepithelial electron dense deposits along the
capillary loops with effacement of overlying foot With d i di GBM t i l iprocesses. With advancing disease, new GBM material is
laid down at the sides of and around the deposits.
Dwi-Lestari
Stages of Membranous Nephropathy
I. Subepithelial electron deposits in GBM, no GBM projection adjacent to deposits.
GII. The are GBM projections between deposits so called Spikes.
III. The deposits become incorporated in b t bbasement membrane.
IV. The deposits start to fade away leaving luscent gaps and a thickened basement membranebasement membrane
V. Normal subepithelial zone of GBM, which has been repaired, and the disturbance has been pushed to thedisturbance has been pushed to the subendothelial zone
Dwi-Lestari
MN : PAS staining
Dwi-Lestari
MN : PAM staining
spikes
Dwi-Lestari
Ig G
C3
wie pmDwi-Lestari
endothelendothel
Subepithelial deposits
Foot processes fusion
Dwi-Lestari
MembranoproliferativeMembranoproliferative Glomerulonephritis (MPGN)
Type I : immune complex mediated. LM, EM : Mesangial hypercellularity with subendothelial and mesangialhypercellularity with subendothelial and mesangial immune complex deposits, capillary wall mesangial interposition, and monocyte infiltration. IF : granular mesangial and capillary wall IgG C3 and IgMmesangial and capillary wall IgG, C3 and IgM.
Type II : Deposition of electron dense material within capillary wall (spindle shape/ sausage) . IF : complement p y ( p p g ) pC3.
Type III : Subepithelial and subendothelial deposits associated with GBM disruption and lamina densaassociated with GBM disruption and lamina densa layering.
All types have double-contoured GBM or Tram track/ rail road appearanceroad appearance
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
IgG MPGN type Iyp
C3Dwi-Lestari
EM : tram track appearance GBMEM : tram track appearance
GBM (blue)
GBM
GBMdeposits
GBM
Mesangial hypercellularity
Dwi-Lestari
MPGN type II : C3
Dwi-Lestari
MPGN type II : Dense Deposit Disease
Dwi-Lestari
Glomerular Disease that caused H t i / N h iti S dHematuria / Nephritic Syndrome
Post streptococcal glomerulonephritis/ Acute glomerulonephritisAcute glomerulonephritis Ig A Nephropathy
Dwi-Lestari
Ig A Nephropathy
LM : global or segmental mesangialLM : global or segmental mesangial hypercellularity; mesangial deposits may be seen with trichromet t c o e
IF : mesagial IgA and C3, co-deposition of mesangial IgG or IgM frequent. Deposits may
i ll d i l h GBMoccasionally extend to involve the GBM.EM : mesangial deposits often with clustering at
the paramesangial basement membranethe paramesangial basement membrane
Dwi-Lestari
Dwi-Lestari
Ig A
C3
Dwi-Lestari
Dwi-Lestari
Erythrocytes in urinary space
Dwi-Lestari
Post streptococal glomerulonephritis
LM : glomerular tufts are enlarged, hypercellular,LM : glomerular tufts are enlarged, hypercellular, with leucocytes in glomerular capillaries. Hypercellularity maybe global or segmental.Hypercellularity maybe global or segmental.
IF : Large, irregular subepitelial, and some mesangial and/or subendothelial depositsmesangial and/or subendothelial deposits, usually with Ig G, Ig M, and complement.EM b ith li l H h d it EM : subepithelial Hump shape deposits some mesangial and subendothelial deposits.
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
S d Gl l DiSecondaryGlomerularDisease
Disease associated with Nephrotic SyndromeDisease associated with Nephrotic Syndrome Amyloid nephropathy
Di b t N h th Diabetes Nephropathy
Disease associated with nephritic nephrotic syndrome or RPGNy
Lupus nephritis Anti GBM antibody Anti GBM antibody
Dwi-Lestari
AmyloidNephropathy
LM : pale acellular eosinophilic material infiltrates mesangial areas and peripheral capillary loops,
t i l ll t i d it b larterioles, small arteries, and peritubular interstitium may also be involved, Congo stained positivepositive
IM : no depositsEM d l i t d fib il f 10 t 12EM : randomly oriented fibrils of 10 to 12 nm
diameter replace the mesangium and GBM
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
DiabeticNephropathy
LM : diffuse or nodular mesangial expansion with thickened GBMsthickened GBMs
IF : pseudolinear deposition of albumin and IgG along GBM non-spesific IgM and complementalong GBM, non spesific IgM and complement may be present.
EM : diffuse or nodular mesangial expansionEM : diffuse or nodular mesangial expansion, thickened GBM
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
Ig GIg G
Dwi-Lestari
Lupus NephritisLupusNephritisLM : WHO classificationLM : WHO classification
I : Normal LM II : Mesangial proliferative glomerulonephritis ( with immune
l li it d t i )complex limited to mesangium) III : Focal proliferative glomerulonephritis IV : Diffuse proliferative glomerulonephritisp g p V : Membranous glomerulonephritis VI : Sclerosing
IF A f ll h f i l b li d l t IF : A full house of immunoglobulins and complements.EM : dense deposits in
II : mesangial II : mesangial III and IV : mesangial, subendothelial, occasional subepithelial V : subepithelial
Dwi-Lestari
Dwi-Lestari
Dwi-Lestari
IF : Full house
Ig GIg M
Ig AIg A
C3 C1qDwi-Lestari
Dwi-Lestari
Fingerprints pattern
Dwi-Lestari
Rapid Progressive GlomerulonephritisRapidProgressiveGlomerulonephritis(RPGN)
Synonym Goodpastures syndrome/ anti GBM
LM : glomerulonephritis without tuft hypercellularity crescents frequenthypercellularity, crescents frequent.
IF : continuous linear IgG and C3 along GBMEM : No deposits
Dwi-Lestari
IgG linear staining
Dwi-Lestari
GlomerulonephritisTreatment
General Management (symptomatic therapy)therapy)
Therapies for spesific glomerular diseases (therapy spesific)(therapy spesific)
Dwi-Lestari
GeneralManagement(symptomatictherapy)
Dwi-Lestari
S t ti ThSymtomatic Therapy
EdemaEdema
Proteinuria
Hypertension
Hyperlipidemia
Hypercoagulable stateHypercoagulable state
Dwi-Lestari
Edema
Focus on sodium restriction and diuretics.Focus on sodium restriction and diuretics. Thiazides are a reasonable treatment choice for
patients with mild edema and normal renalpatients with mild edema and normal renal function.
most patients will require a loop diuretic such as furosemide for adequate sodium balance.
Dwi-Lestari
P t i iProteinuriaThe cornerstone management of proteinuria
inhibition of the renin-angiotensin system (ACEIinhibition of the renin angiotensin system (ACEI or ARBs)
R d d i t l l d dReduced intraglomerular pressure reduced protein filtration.
Evidence in diabetes of ACEi and ARBs Proteinuria may also be reduced by loweringProteinuria may also be reduced by lowering
patients mean arterial pressure (MAP)
Dwi-Lestari
H t iHypertension The underlying pathophysiology of hypertension in
primary glomerular disease :primary glomerular disease :oPrimary renal NaCl retention volume
iexpansiono Intrarenal activation of renin-angiotensin systemg yoActivation sympathetic nervous systemo vasoconstrictor (thromboxane, endothelin) and vasorelaxant (NO, prostaglandins)
Dwi-Lestari
MDRD Study Hypertension control improves proteinuria & GFR
0
Hypertension control improves proteinuria & GFR
-3
l
i
n
e
-6
3
F
R
D
e
c
l
m
i
n
/
y
r
)
9
-6
e
o
f
G
F
(
m
L
/
m
Protein Excretion-9
R
a
t
e
1.0 g/d
Protein Excretion
-1280 85 90 95 100 105 110
Mean Follow Up MAP (mmgHg)Mean Follow-Up MAP (mmgHg)
Peterson, Annal Int Med 123:1995Dwi-Lestari
G lMaintain SBP of 120-130 mmHg and DBP of 70-80 mmHg. Do not ll di t li BP t f ll b ll 70 80 H if t tiGoals : allow diastolic BP to fall bellow 70-80 mmHg if symptomatic coronary
artery disease is presentACEi or ARB preferredACEi or ARB preferred
Use NaCl restriction and/or diuretic (thiazides, loop acting, spironolactone oreplerenone) to augment effectiveness
Agents :p p ) g
Direct renin inhibitors may also be used selectively
Adjunctive therapy with calcium channel blockers (CCB) may beAdjunctive therapy with calcium channel blockers (CCB) may be used for optimal BP controlFor mono therapy with ACEi or ARB, the maximum tolerated dosage
Dosage :
should be used, preferably to assure both daytime and night-time control of BP to desire goals. Ambulatory monitoring of 24-h BP may be neededDosage : be needed.For combination ACEi & ARB therapy the maximum recommended dosage of each agent should be used, with monitoring of serum g g gpotassium levels.
Ponticelli, Glassock, 2009Dwi-Lestari
H perlipidemiaHyperlipidemia Low in total cholesterol and saturated fat; vegetarian/ soy diet
Stop smooking
Modest exercise
Avoid excessive alcohol
HMG co reductase inhibitors (lovastatin simvastatinHMG co-reductase inhibitors (lovastatin, simvastatin, pravastatin, atorvastatin, resuvastatin, flufastatin)
Probucol (may lower HDL )Probucol (may lower HDL2)
Bile acid sequestering agent (cholestyramine, cholestipol, lli ll id)psyllium colloid)
Dwi-Lestari
Hypercoagulable stateHypercoagulablestateIncreased (prothrombotic)Increased (prothrombotic)
FibrinogenPlatelets (and platelet adhesiveness)Plasma viscocity (cholesterol, lipid)Lipoproten (a)Plasminogen activator inhibitorPlasminogen activator inhibitor
Decreased (antithrombotic)
Active protein CActive protein CActive protein SAnti thrombin III
Long term anticoagulation is recommended for patients with documentedrecommended for patients with documented thrombotic episodes.
Dwi-Lestari
Specific Therapies forSpecific Therapies for Glomerulonephritis
Dwi-Lestari
1. Minimal change glomerulopathy.1. Minimal change glomerulopathy.
Hi h d d i (1 k i 80 ) i High-dose prednisone (1 mg per kg, maximum, 80 mg) is used as primary therapy for at least 12 weeks.
F l i d t id d d dditi For relapsing and steroid dependence cases addition of cytotoxic agents (e.g., cyclophosphamide or chlorambucil) cyclosporine A or possiblychlorambucil), cyclosporine A, or possibly mycophenolate mofetil, may be effective.
Dwi-Lestari
2 Membranous nephropathy2. Membranous nephropathy.
This disease is often slowly progressive and patients may have spontaneous remissions.
Certain patients high risk for progressive renal injury.
Clinical risk factors heavy proteinuria >8 mg per day, hypertension, diminished GFR, male gender, and greater than 20% tubulointerstitial fibrosis on renal biopsy.
Low Risk Steroid effective. High risk : steroids combined with a cytotoxic agent.g y g
Dwi-Lestari
3 MPGN3. MPGN
5% f l l di i d lt 5% of glomerular disease in adults, tend to carry a poor renal prognosis. 60% patients will progress to ESRD in 10 years. Unfortunatel no established therapy exists for MPGNUnfortunatel, no established therapy exists for MPGN. Secondary causes must be fully evaluated, because
diseases such as chronic bacterial infection hepatitis Cdiseases such as chronic bacterial infection, hepatitis C infection, and cryoglobulinemis, as well as leukemias and lymphomas all have therapies that may lead to remission y p p yof the renal disease.
Dwi-Lestari
4 F l d t l l l l i4. Focal and segmental glomerulosclerosis
20% of idiopathic nephrotic syndrome in adults FSGS FSGS and MCD within the same spectrum of
disease but the prognosis is significantly worse in FSGSFSGS.
High-dose corticonsteroid therapy 30% of patients will achieve remission
70% fail cytotoxic agents such as cyclosporin, cyclophospamide, or chlorambucil.
Dwi-Lestari
5. IgA nephropathy (Bergers disease)g p p y ( g )
the most common form of primary glomerular disease, Slowly progressive renal disease ESRD in 20% to 40%
(20 years)
a minority of patients RPGN corticosteroids (? further studies needed) patientscorticosteroids (? further studies needed) patients
with proteinuria >1 mg per day (0.5 mg per kg on alternate days).
For crescentic disease, short-term, high-dose prednisone may be of benefit.
The use of cytotoxic agents , MMF sometimes employed in patients with rapidly progressive disease.p y p p y p g
Dwi-Lestari
6. Lupus nephritis
Lupus nephritis is the paradigmatic immune complex disease of the kidney with widecomplex disease of the kidney with wide spectrum diseases. th f i l di t d therapy for immune complex-mediated glomerulonephritis include high-dose
ti t id t d h l tcorticosteroids, cytoxan, and mycophenolate mofetil is effective to be of benefit.
Dwi-Lestari
7 Anti GBM disease and Goodpastures7. Anti-GBM disease and Goodpasture s syndrome
PA : Crescents and immunofluorescent a linear pattern staining for IgG an anti-GBM autoantibody.
Clinically, as isolated renal dysfunction (anti-GBM disease) y, y ( )or as renal disease in conjunction with pulmonary involvement (Goodpastures syndrome)
Treatment combination of high-dose steroids, cytoxan therapy, and plasmapheresis to remove the anti-GBM antibody.
Oliguric patients poor renal prognosis.
Dwi-Lestari
Dwi-Lestari
Clinical syndrome Manifestation Major etiologies
Asymptomatic proteinuria Urinary protein excretion < 2 g/d Low-grade glomerular disease ( I A h th MN ( IgA nephropathy, MN or MPGN)Heriditary glomerular disease (Alports syndrome)Tubulointerstitial disease
Asymptomatic hematuria Urinary RBCs > 2/ HPF (spun sediment)
Low-grade glomerular disease ( IgA nephropathy, Thin basement membran disease)basement membran disease)
Nephrotic syndrome Heavy proteinuria (>3,5 g/d), edema, high serum cholesterol, urine lipids
MCNS, FSGS, MN, MPGNDiabetic nephropathyAmyloid (myeloma LCDD)Amyloid (myeloma, LCDD)Fibrillary GN
RPGN Presents as GN with ARF (oliguria, rising serum creatinin)
Anti GBM nephritis (Goodpastures)Vasculitis Syndromes (Wegeners polyangiitis, HSP, mixed cryoglobulinemia)Immune-complex associated Immune complex associated (IgAN, poststrep GN)
Nephritic syndrome RBCs, RBC cast, proteinuria, hypertension, renal disfunction.
Poststreptococcal AGNOther post infectious GN (abcess, endocarditis)IgA nephropathyLN (WHO class III/ IV)Dwi-Lestari